Description
Ipamorelin ( IPAM, NNC 26-0161)
Ipamorelin stimulates growth hormone secretion by binding to the growth hormone secretagogue receptor (GHSR) in the pituitary gland. It differs from other growth hormone-releasing peptides in that it does not substantially increase levels of ACTH, cortisol, prolactin, or aldosterone, which contributes to its high specificity for stimulating growth hormone.
Also known as: IPAM, NNC 26-0161
•Status: Investigational – Phase II trials have been halted. Currently classified as FDA Category 2, with a planned reclassification to Category 1 pending the April 15, 2026, HHS announcement. However, it remains under Category 2 under existing regulations until the FDA formally issues a new rule; subject to review by the PCAC on July 23–24, 2026. Evidence level based on human clinical trials.
•Typical dosage: 200–300 mcg administered via subcutaneous injection, two to three times per day.
•Studied for potential use in anti-aging, muscle growth, improving sleep quality, and enhancing recovery.
•Typical dosage: 200–300 mcg administered via subcutaneous injection, two to three times per day.
•Studied for potential use in anti-aging, muscle growth, improving sleep quality, and enhancing recovery.
Reviews
There are no reviews yet.